Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial (vol 17, pg 342, 2023)

被引：0
|
作者：
Witztum, Joseph L. [1 ]
Gaudet, Daniel [2 ,3 ]
Arca, Marcello [4 ]
Jones, Alan [5 ]
Soran, Handrean [6 ]
Gouni-Berthold, Ioanna [7 ,8 ]
Stroes, Erik S. G. [9 ]
Alexander, Veronica J. [10 ]
Jones, Richard [11 ]
Watts, Lynnetta [10 ]
Xia, Shuting [10 ]
Tsimikas, Sotirios [1 ,10 ]
机构：
[1] Univ Calif San Diego, Dept Med, Room 1081,9500 Gilman Dr, La Jolla, CA 92093 USA
[2] Univ Montreal, Community Genom Med Ctr, Dept Med, Lipidol Unit, 930 Jacques Cartier Est, Chicoutimi, PQ G7H 7K9, Canada
[3] ECOGENE 21, 930 Jacques Cartier Est, Chicoutimi, PQ G7H 7K9, Canada
[4] Univ Roma La Sapienza, Dept Translat & Precis Med, Viale Univ 37, I-00185 Rome, Italy
[5] Univ Hosp Birmingham NHS Fdn Trust, Heartlands Hosp, Bordesley Green E, Birmingham B9 5SS, England
[6] Manchester Univ NHS Fdn Trust, Manchester Royal Infirm, Oxford Rd, Manchester M13 9WL, England
[7] Univ Cologne, Fac Med, Ctr Endocrinol Diabet & Prevent Med, Kerpener Str 62, D-50937 Cologne, Germany
[8] Univ Hosp Cologne, Kerpener Str 62, D-50937 Cologne, Germany
[9] Acad Med Ctr, Dept Vasc Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[10] Ionis Pharmaceut, 2855 Gazelle Court, Carlsbad, CA 92010 USA
[11] Akcea Therapeut, St James House,72 Adelaide Rd 2, Dublin D02 Y017, Ireland
来源：
JOURNAL OF CLINICAL LIPIDOLOGY | 2024年 / 18卷 / 03期
关键词：
D O I：
10.1016/j.jacl.2023.09.010
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：e482 / e483
页数：2
相关论文
共 50 条
  • [1] Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial
    Witztum, Joseph L.
    Gaudet, Daniel
    Arca, Marcello
    Jones, Alan
    Soran, Handrean
    Gouni-Berthold, Ioanna
    Stroes, Erik S. G.
    Alexander, Veronica J.
    Jones, Richard
    Watts, Lynnetta
    Xia, Shuting
    Tsimikas, Sotirios
    JOURNAL OF CLINICAL LIPIDOLOGY, 2023, 17 (03) : 342 - 355
  • [2] Plozasiran and Triglyceride Levels in Hypertriglyceridemia: Long-Term Efficacy and Safety Data From Subjects in an Open-Label Extension Trial
    Ballantyne, Christie
    Watts, Gerald
    Rosenson, Robert
    Vasas, Szilard
    Pall, Denes
    Clifton, Peter
    Nicholls, Stephen
    Azizad, Masoud
    Fu, Ran
    Muhsin, Maan
    Melquist, Stacey
    Hellawell, Jennifer
    Gaudet, Daniel
    CIRCULATION, 2024, 150
  • [3] Pegloticase Long-Term Safety: Data From the Open-Label Extension Trial.
    Becker, Michael A.
    Baraf, Herbert S. B.
    Yood, Robert A.
    Dillon, Aileen M.
    Vazquez-Mellado, Janitzia
    Ottery, Faith D.
    Khanna, Dinesh
    Sundy, John S.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S69 - S70
  • [4] Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program
    Farnier, Michel
    Hovingh, G. Kees
    Langslet, Gisle
    Dufour, Robert
    Baccara-Dinet, Marie T.
    Din-Bell, Chantal
    Manvelian, Garen
    Guyton, John R.
    ATHEROSCLEROSIS, 2018, 278 : 307 - 314
  • [5] MPOWERED Trial Open-Label Extension: Long-term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly
    Fleseriu, Maria
    Molitch, Mark
    Dreval, Alexander
    Pokramovich, Yulia
    Bondar, Irina
    Poteshkin, Yury
    Macut, Djuro
    Obermayer-Pietsch, Barbara
    Gilgun-Sherki, Yossi
    Haviv, Asi
    Biermasz, Nienke
    Strasburger, Christian J.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (12): : 3214 - 3222
  • [6] Long-Term Safety and Efficacy of Add-on Cannabidiol (CBD) Treatment in Patients with Dravet Syndrome in an open-label, Extension Trial
    Halford, Jonathan
    Scheffer, Ingrid
    Nabbout, Rima
    Sanchez-Carpintero, Rocio
    Malawsky, Yael Shiloh
    Wong, Matthew
    Checketts, Daniel
    VanLandingham, Kevan
    NEUROLOGY, 2019, 92 (15)
  • [7] Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: Results of a long-term open-label extension trial
    Patel, Anup D.
    Mazurkiewicz-Beldzinska, Maria
    Chin, Richard F.
    Gil-Nagel, Antonio
    Gunning, Boudewijn
    Halford, Jonathan J.
    Mitchell, Wendy
    Scott Perry, Michael
    Thiele, Elizabeth A.
    Weinstock, Arie
    Dunayevich, Eduardo
    Checketts, Daniel
    Devinsky, Orrin
    EPILEPSIA, 2021, 62 (09) : 2228 - 2239
  • [8] LONG-TERM EFFICACY AND SAFETY OF LOMITAPIDE IN PATIENTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS): DATA FROM THE LOCHNES STUDY
    Giammanco, A.
    Cefalu, A.
    D'Erasmo, L.
    Iannuzzo, G.
    Noto, D.
    Montali, A.
    Zambon, A.
    Forte, F.
    Suppressa, P.
    Giannini, S.
    Barbagallo, C. M.
    Ganci, A.
    Nardi, E.
    Brancatelli, G.
    Caldarella, R.
    Ciaccio, M.
    Arca, M.
    Averna, M.
    ATHEROSCLEROSIS, 2023, 379
  • [9] Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: An open-label extension trial
    McConville, B
    Carrero, L
    Sweitzer, D
    Potter, L
    Chaney, R
    Foster, K
    Sorter, M
    Friedman, L
    Browne, K
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2003, 13 (01) : 75 - 82
  • [10] Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial
    Devinsky, Orrin
    Nabbout, Rima
    Miller, Ian
    Laux, Linda
    Zolnowska, Marta
    Wright, Stephen
    Roberts, Claire
    EPILEPSIA, 2019, 60 (02) : 294 - 302
12345